Arizona State Retirement System Raises Stock Position in Guardant Health, Inc. (NASDAQ:GH)
Arizona State Retirement System grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 1.1% during ...
1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune ...
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health has an expanding pipeline that could significantly boost its future market potential. Check out my ...
Guardant Health (GH) Receives a Buy from Barclays
In a report released today, Luke Sergott from Barclays maintained a Buy rating on Guardant Health (GH – Research Report), with a price target ...
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...
Guardant Health Shares Rise After ADLT Status for Shield Blood Test
Guardant Health said the CMS determination confirms that the Shield test meets the criteria for ADLT status, which is reserved for innovative products that provide novel clinical information that ...
Business Wire2d
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid ...
Guardant Health rises after Medicare ADLT status for colorectal cancer test
Guardant Health ( NASDAQ: GH) traded higher in the morning hours on Tuesday after the company announced that the U.S. Centers ...
CMS approves Guardant Health ADLT status for Shield CRC screening test
Guardant Health (GH) announced the Centers for Medicare & Medicaid Services CMS has approved Advanced Diagnostic Laboratory Test ADLT ...
Guardant Health (NASDAQ:GH) Price Target Raised to $52.00
Guardant Health (NASDAQ:GH – Free Report) had its target price lifted by Morgan Stanley from $42.00 to $52.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating ...